+86-27-65522453 sales@sun-shinechem.com

Danoprevir

Catalog No.: 16070107
Cas No.: 850876-88-9
Purity : 98% by HPLC 
16070107 - Danoprevir | CAS 850876-88-9

Catalog number : 16070107

CAS number : 850876-88-9

分子式 : C35H46FN5O9S 

分子量 : 731.83 

Iupac 化学名称 : (2R,13aS,14aR,16aS,Z)-6-((tert-butoxycarbonyl)amino)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate 

Smile : FC1=C2CN(CC2=CC=C1)C(=O)O[C@@H]1C[C@@H]2N(C(C(CCCCC\C=C/[C@H]3[C@](NC2=O)(C3)C(NS(=O)(=O)C3CC3)=O)NC(=O)OC(C)(C)C)=O)C1

InChiKey : ZVTDLPBHTSMEJZ-QIFYYAQYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词RG7227; RG 7227; 
英文同义词RG7227; RG 7227; 
分子式C35H46FN5O9S 
分子量731.83 
外观Solid powder 
纯度98% by HPLC 
可溶性Soluble in DMSO 
存储-20 ºC for 3 years 
运输条件Shipped under ambient temperature 
SmileFC1=C2CN(CC2=CC=C1)C(=O)O[C@@H]1C[C@@H]2N(C(C(CCCCC\C=C/[C@H]3[C@](NC2=O)(C3)C(NS(=O)(=O)C3CC3)=O)NC(=O)OC(C)(C)C)=O)C1
InChiKeyZVTDLPBHTSMEJZ-QIFYYAQYSA-N
InChiInChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27?,28+,35-/m1/s1
Coming soon.
Danoprevir, also known as ITMN-191 and RG-7227, is under development by InterMune Inc and Roche Holding AG, is a promising, potent NS3/4A protease inhibitor for the oral treatment of HCV infection. Preclinical data demonstrated that danoprevir binds with high affinity and dissociates slowly from the HCV NS3 protease, allowing high liver drug exposure with only modest plasma drug exposure. A phase Ib, 'IFN-free' clinical trial demonstrated that danoprevir, combined with the HCV polymerase inhibitor RG-7128 (Pharmasset Inc/Roche Holding AG), was effective in reducing HCV-RNA levels in a large proportion of treatment-naÃve patients with HCV infection and in approximately half of previously non-responsive patients with HCV-1 infection, without resistance or safety concerns. 

850876-88-9 - Request Bulk Quote

×
850876-88-9 - Request Bulk Quote
Change